CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases

G Sharma, AR Sharma, M Bhattacharya, SS Lee… - Molecular Therapy, 2021 - cell.com
At present, the idea of genome modification has revolutionized the modern therapeutic
research era. Genome modification studies have traveled a long way from gene …

Antibiotic therapy as personalized medicine–general considerations and complicating factors

C Moser, CJ Lerche, K Thomsen, T Hartvig… - Apmis, 2019 - Wiley Online Library
The discovery of antibiotic drugs is considered one of the previous century's most important
medical discoveries (Medicine's 10 greatest discoveries. New Haven, CT: Yale University …

[HTML][HTML] The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects

S Van den Bossche, E De Broe… - European …, 2021 - publications.ersnet.org
Chronic airway colonisation by Pseudomonas aeruginosa, a hallmark of cystic fibrosis (CF)
lung disease, is associated with increased morbidity and mortality and despite aggressive …

[HTML][HTML] Personalized medicine based on nasal epithelial cells: comparative studies with rectal biopsies and intestinal organoids

IAL Silva, V Railean, A Duarte, MD Amaral - Journal of Personalized …, 2021 - mdpi.com
As highly effective CFTR modulator therapies (HEMT) emerge, there is an unmet need to
find effective drugs for people with CF (PwCF) with ultra-rare mutations who are too few for …

Cystic fibrosis: Physiopathology and the latest pharmacological treatments

C Fonseca, J Bicker, G Alves, A Falcão… - Pharmacological …, 2020 - Elsevier
Cystic fibrosis (CF) is a lethal autosomal recessive genetic disease, caused by a mutation in
the cystic fibrosis transmembrane conductance regulator gene (CFTR), which primarily …

Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients

JA Bartell, LM Sommer, RL Marvig… - European …, 2021 - publications.ersnet.org
Whenever Pseudomonas aeruginosa is cultured from cystic fibrosis (CF) patient airways, the
primary goal is eradication by antibiotic therapy. Success is defined by≥ 6 months of …

Evolving nutritional needs in cystic fibrosis

T Frantzen, S Barsky, G LaVecchia, M Marowitz… - Life, 2023 - mdpi.com
The course of cystic fibrosis (CF) as a nutritional illness is diverging since the introduction of
highly effective modulator therapy, leading to more heterogeneous phenotypes of the …

[HTML][HTML] Immune Response to Biofilm Growing Pulmonary Pseudomonas aeruginosa Infection

K Thomsen, N Høiby, PØ Jensen, O Ciofu, C Moser - Biomedicines, 2022 - mdpi.com
Biofilm infections are tolerant to the host responses and recalcitrance to antibiotic drugs and
disinfectants. The induced host-specific innate and adaptive immune responses by …

[HTML][HTML] In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments

L Christophersen, FA Schwartz, CJ Lerche… - Journal of Cystic …, 2020 - Elsevier
Background Pseudomonas aeruginosa is difficult to eradicate from the lungs of cystic
fibrosis (CF) patients due to biofilm formation. Organs and blood are independent …